The Merck KGaA company collaborated with actress and patient advocate Selma Blair for the I Was Ready for Change campaign.

Thousands of NHS patients in England with multiple sclerosis (MS) are set to benefit from a life-changing ‘take at home’ tablet, as the NHS becomes the first healthcare system in Europe to roll it out ...

Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence ...

The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...

The Scottish Medicines Consortium is reviewing cladribine for broader use in relapsing forms of the condition.

The health service is thought to be the first in Europe to widely rollout cladribine, also known as Mavenclad and made by Merck. It has been approved by the National Institute for Health and Care ...

The medication, which will be rolled out to patients with relapsing-remitting MS, is thought to be the first in Europe to be ...

Merck is looking for new assets as one of its key growth drivers, multiple sclerosis drug Mavenclad, will face patent expiry in 2026. The German company’s goal is to achieve a 50-50 split ...

Find insight on Merck KGaA, Bayer, Jazz Pharmaceuticals and the use of AI in China’s healthcare sector in the latest Market Talks covering Health Care.

Zeit Aktuelle Nachrichten Do Weitere Übernahmen erwartet - Bayer, BioNxt Solutions, Merck KGaA Die aggressive Zollpolitik der neuen US-Administration mit US-Präsident Trump hat einige ...

The second deal is with German pharma company Merck for its multiple sclerosis drug Mavenclad (cladribine), and involves a new outcomes-based pricing agreement. Simon Stevens hailed the Merck ...